PMID- 8825126
OWN - NLM
STAT- MEDLINE
DCOM- 19961114
LR  - 20190905
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 38
IP  - 1
DP  - 1996
TI  - The efficacy of 9-cis retinoic acid in experimental models of cancer.
PG  - 85-96
AB  - 9-cis retinoic acid (9-cis RA) is a retinoid receptor pan-agonist that binds with 
      high affinity to both retinoic acid receptors (RARs) and retinoid X receptors 
      (RXRs). Using a variety of in vivo and in vitro cancer models, we present 
      experimental data that 9-cis RA has activity as a potential chemotherapeutic 
      agent. Treatment of the human promyelocytic leukemia cell line HL-60 with 9-cis 
      RA decreases cell proliferation, increases cell differentiation, and increases 
      apoptosis. Induction of apoptosis correlates with an increase in tissue 
      transglutaminase (type II) activity. In vivo, 9-cis RA induces complete tumor 
      regression of an early passage human lip squamous cell carcinoma xenograft. 
      Finally, 9-cis RA inhibits the anchorage-independent growth of the human breast 
      cancer cell lines MCF-7 and LY2 (an antiestrogen-resistant MCF-7 variant). 
      Transient co-transfection assays indicate that 9-cis RA inhibits estrogen 
      receptor transcription of an ERE-tk-LUC reporter through RAR or RXR receptors. 
      These data suggest that retinoid receptors can antagonize estrogen-dependent 
      transcription and provides one possible mechanism for the inhibition of cell 
      growth by 9-cis RA in breast cancer cell lines. In summary, these findings 
      present evidence that 9-cis RA has a wide range of activities in human cancer 
      models.
FAU - Gottardis, M M
AU  - Gottardis MM
AD  - Department of Pharmacology, Ligand Pharmaceuticals, San Diego CA, USA.
FAU - Lamph, W W
AU  - Lamph WW
FAU - Shalinsky, D R
AU  - Shalinsky DR
FAU - Wellstein, A
AU  - Wellstein A
FAU - Heyman, R A
AU  - Heyman RA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 5688UTC01R (Tretinoin)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Breast Neoplasms/drug therapy
MH  - Carcinoma, Squamous Cell/drug therapy
MH  - Cell Division/drug effects
MH  - HL-60 Cells/drug effects
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - Tretinoin/metabolism/pharmacology/*therapeutic use
RF  - 57
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 10.1007/BF01803787 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 1996;38(1):85-96. doi: 10.1007/BF01803787.